In this post
IASLC World Conference on Lung Cancer, the world's premier event for physicians and scientists advancing the fight against world's deadliest cancer, is taking place from September 7th till September 10 in Barcelona, Spain.
Four scientific presentations will feature independent validation results of Optellum's solutions by leading medical centres in USA and Europe, and highlight the potential for AI-based Clinical Decision Support software solutions to accelerate early lung cancer diagnosis and treatment.
We invite all attendees to try interactive software prototypes & learn more about validation results at the joint Education Exhibit between Optellum and Oxford University Hospitals (Booth 207 NIHR IDEAL & Optellum, Exhibit Hall).
Sunday 08 Sept 2019 - 09:45 - 10:30 and 16:45 - 18:00;
Location: Exhibit Hall - P1.11 - Screening and Early Detection
Vanderbilt University clinicians present results that indicate
Optellum LCP-AI risk model may shorten time to a cancer diagnosis and treatment
by up to 156 days compared to guidelines.
Monday 9 Sept 2019; 11:00 - 12:30; Location: Hilton
Head (1978) - OA06 - Refining Lung Cancer Screening
University
of Groningen Medical Centre show that the performance of a Deep Learning
perifissural nodule classifier is similar to that of 3 radiologists who
labelled the nodules independently, and is within the inter-reader variability
of radiologists.
Monday 9 Sept 2019; 09:45 - 10:30 and 16:45 - 18:00;
Location: Exhibit Hall – P2.11 - Screening and Early Detection
P2.11-13
- What Is the Impact of Localised Data When Training Deep Neural Networks for
Lung Cancer Prediction?
Royal Brompton and Harefield Hospital clinicians show that adding incidental data in the training sets improved the LCP model performance when used on incidental data.
P2.11-46
- Could Malignancies Diagnosed During Round 2 of Screening Be Worked Up Sooner?
Wake Forest Baptist Health clinicians show that diagnostic work-up of cases referred at second screening could have been triggered earlier for the majority of late diagnosed and early manifesting cancers when the LCP score was utilised.
